ESMO 2019: Combination immunotherapy drugs offer new hope for melanoma patients 28 Sep 2019 A combination of two immunotherapy drugs, ipilimumab and nivolumab, stops or reverses the progression of advanced melanoma – with long term survival rates hitting an all-time high – according to a study presented at the ESMO Congress. Find out more Show/Hide
Blood test could indicate which patients will respond to immunotherapy 30 Jan 2018 The test gives a measure of a patient’s immune system health by comparing the number of neutrophils with the number of lymphocytes. Find out more Show/Hide
Breakthrough for advanced head and neck cancer patients as nivolumab made available on the Cancer Drugs Fund 13 Oct 2017 The immunotherapy nivolumab has today been made available on the Cancer Drugs Fund (CDF) for patients with head and neck cancer if the disease progresses within six months of receiving platinum chemotherapy. Find out more Show/Hide
ICR reacts to decision to make the immunotherapy nivolumab available on the Cancer Drugs Fund for non-small cell lung cancers 20 Sep 2017